IRLAB: Invitation to the interim report for Q2 2026 presentation and webcast

Gothenburg, Sweden, August 20, 2026 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company will hold a presentation in conjunction with the publication of the interim report for the period January – June 2026. The interim report will be published on Wednesday, August 26, 2026, at 07:00 CEST.

IRLAB’s Drug Candidate IRL757 Receives the Generic Name linepemat from the WHO

New number of shares and votes in IRLAB Therapeutics AB